Summit Therapeutics Inc. — Director's Dealing 2020

Sep 18, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2020-09-18

Reporting Person: Houbiers Jos (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15512	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.92	2028-10-19	Common Stock (37288)		Direct
Stock Option (right to buy)	$1.79	2029-03-29	Common Stock (44000)		Direct
Stock Option (right to buy)	$3.31	2030-07-08	Common Stock (300000)		Direct
Stock Option (right to buy)	$3.17	2030-07-09	Common Stock (20000)		Direct

Footnotes

F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Summit Therapeutics Inc., a Delaware corporation ("New Summit") to the attributes of Summit Therapeutics plc, a public limited company incorporated in England and Wales ("Old Summit"), the predecessor issuer. The succession occurred following the effectiveness, on September 18, 2020, of a United Kingdom court-approved scheme of arrangement in which every five ordinary shares, 0.01 pound sterling par value per share, of Old Summit were exchanged for one share of common stock, $0.01 par value per share, of New Summit, which resulted in New Summit becoming the holding company of Old Summit and its subsidiaries.

F2: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.

F3: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.

F4: The option was granted on July 8, 2020. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date, subject to the satisfaction of certain performance targets.

F5: The option was granted on July 9, 2020. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date, subject to the satisfaction of certain performance targets.